Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Artiva Biotherapeutics is initiating a Phase 3 registrational trial in the second half of 2026 evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 patients with refractory rheumatoid arthritis, with topline results expected by the end of 2028. Updated Phase 2a basket-trial data are expected in H2 2026 from at least 20 refractory RA patients with at least six months of follow-up — including at least 10 who would meet Phase 3 eligibility criteria — plus at least 10 Sjögren disease and at least five systemic sclerosis patients.
Key figures
- Drug Name
- AlloNK (AB-101)
- Phase Of Trial
- Phase 3
- Cash runway
- into 2029
- Acr50 target
- >50%
- Phase3 design
- AlloNK plus rituximab versus rituximab alone in refractory RA
- Minimum follow up
- at least six months
- Phase3 patient count
- approximately 150
- Topline readout timing
- by end of 2028
- Phase3 primary endpoint
- ACR50 response at six months
- Acr50 control arm expected
- ~20%
- Ra patients with updated data
- at least 20
- Sjd patients with updated data
- at least 10
- Ssc patients with updated data
- at least 5
- Phase3 eligible patients in dataset
- at least 10
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.